Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$1.06
-3.6%
$1.16
$0.82
$4.08
$284.36M0.263.87 million shs3.98 million shs
Journey Medical Corporation stock logo
DERM
Journey Medical
$6.85
+2.2%
$5.74
$4.31
$9.56
$188.58M1.09215,403 shs308,008 shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$13.72
-2.4%
$13.32
$6.43
$17.15
$398.98M0.97192,927 shs286,549 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.49
+2.1%
$1.28
$0.98
$1.60
$1.13B1.52.71 million shs2.37 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
+0.92%+11.79%+7.84%-20.86%-69.78%
Journey Medical Corporation stock logo
DERM
Journey Medical
+4.20%+9.66%+12.42%-1.90%+5.02%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
+5.16%+16.49%+0.79%+15.53%+97.47%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+2.10%+5.04%+14.96%+22.69%+14.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$1.06
-3.6%
$1.16
$0.82
$4.08
$284.36M0.263.87 million shs3.98 million shs
Journey Medical Corporation stock logo
DERM
Journey Medical
$6.85
+2.2%
$5.74
$4.31
$9.56
$188.58M1.09215,403 shs308,008 shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$13.72
-2.4%
$13.32
$6.43
$17.15
$398.98M0.97192,927 shs286,549 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.49
+2.1%
$1.28
$0.98
$1.60
$1.13B1.52.71 million shs2.37 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
+0.92%+11.79%+7.84%-20.86%-69.78%
Journey Medical Corporation stock logo
DERM
Journey Medical
+4.20%+9.66%+12.42%-1.90%+5.02%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
+5.16%+16.49%+0.79%+15.53%+97.47%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+2.10%+5.04%+14.96%+22.69%+14.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
2.20
Hold$4.67340.25% Upside
Journey Medical Corporation stock logo
DERM
Journey Medical
2.25
Hold$13.0089.78% Upside
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2.75
Moderate Buy$20.2947.86% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.17
Hold$1.554.03% Upside

Current Analyst Ratings Breakdown

Latest AKBA, OPK, ENTA, and DERM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
Reiterated RatingBuy$20.00
5/18/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
UpgradeSell (E+)Sell (D-)
5/6/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Reiterated RatingSell (E+)
5/6/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
DowngradeHoldStrong Sell
5/4/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeSell (D-)Sell (E+)
4/29/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeOutperformMarket Perform
4/21/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
Reiterated RatingSell (D-)
4/20/2026
Journey Medical Corporation stock logo
DERM
Journey Medical
Reiterated RatingSell (D-)
4/20/2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
Reiterated RatingSell (D-)
4/7/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
UpgradeStrong SellHold
4/7/2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Reiterated RatingBuy$4.00
(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$236.20M1.20N/AN/A$0.12 per share8.83
Journey Medical Corporation stock logo
DERM
Journey Medical
$61.86M3.05N/AN/A$0.96 per share7.14
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$65.32M6.11N/AN/A$3.03 per share4.53
OPKO Health, Inc. stock logo
OPK
OPKO Health
$606.90M1.85N/AN/A$1.67 per share0.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$5.34M-$0.08N/AN/AN/A-8.83%-62.72%-5.66%8/6/2026 (Estimated)
Journey Medical Corporation stock logo
DERM
Journey Medical
-$11.43M-$0.37N/A4.72N/A-14.82%-35.57%-10.88%8/11/2026 (Estimated)
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$81.89M-$2.59N/AN/AN/A-89.56%-64.04%-20.22%8/10/2026 (Confirmed)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.27N/AN/AN/A-36.63%-16.78%-10.98%7/30/2026 (Estimated)

Latest AKBA, OPK, ENTA, and DERM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.07-$0.08-$0.01-$0.08$15.47 million$15.96 million
5/11/2026Q2 2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$0.46-$0.45+$0.01-$0.45$17.03 million$17.16 million
5/7/2026Q1 2026
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.01-$0.03-$0.02-$0.03$51.67 million$53.54 million
4/28/2026Q1 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.07N/A-$0.07$130.51 million$124.20 million
3/25/2026Q4 2025
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.06-$0.04+$0.02-$0.04$18.86 million$16.08 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Journey Medical Corporation stock logo
DERM
Journey Medical
N/AN/AN/AN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
1.33
1.40
1.33
Journey Medical Corporation stock logo
DERM
Journey Medical
0.74
1.72
1.47
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/A
3.84
3.84
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.28
3.61
3.17

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Journey Medical Corporation stock logo
DERM
Journey Medical
7.25%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
94.99%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.30%
Journey Medical Corporation stock logo
DERM
Journey Medical
14.53%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
11.48%
OPKO Health, Inc. stock logo
OPK
OPKO Health
44.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
430268.26 million256.72 millionOptionable
Journey Medical Corporation stock logo
DERM
Journey Medical
9027.53 million23.53 millionN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
16029.08 million25.74 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373755.09 million417.42 millionOptionable

Recent News About These Companies

Spotlight On Promising Penny Stocks For May 2026

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$1.06 -0.04 (-3.64%)
Closing price 04:00 PM Eastern
Extended Trading
$1.06 -0.01 (-0.47%)
As of 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Journey Medical stock logo

Journey Medical NASDAQ:DERM

$6.85 +0.15 (+2.24%)
Closing price 04:00 PM Eastern
Extended Trading
$6.96 +0.11 (+1.55%)
As of 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Enanta Pharmaceuticals stock logo

Enanta Pharmaceuticals NASDAQ:ENTA

$13.72 -0.34 (-2.42%)
Closing price 04:00 PM Eastern
Extended Trading
$13.72 0.00 (0.00%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.49 +0.03 (+2.05%)
Closing price 04:00 PM Eastern
Extended Trading
$1.50 +0.01 (+0.34%)
As of 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.